Is Radiofrequency Ablation Effective In Treating Barrett’s Esophagus Patients with High-Grade Dysplasia? by Karnado, Ariana S
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2017
Is Radiofrequency Ablation Effective In Treating
Barrett’s Esophagus Patients with High-Grade
Dysplasia?
Ariana S. Karnado
Philadelphia College of Osteopathic Medicine
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Gastroenterology Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Karnado, Ariana S., "Is Radiofrequency Ablation Effective In Treating Barrett’s Esophagus Patients with High-Grade Dysplasia?"
(2017). PCOM Physician Assistant Studies Student Scholarship. 383.
https://digitalcommons.pcom.edu/pa_systematic_reviews/383
  
 
 
 
 
 
Is Radiofrequency Ablation Effective In Treating Barrett’s Esophagus Patients with High-
Grade Dysplasia? 
 
 
 
 
 
 
 
Ariana S. Karnado, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
 
 
 
Department of Physician Assistant Studies 
 
Philadelphia College of Osteopathic Medicine 
 
Philadelphia, Pennsylvania 
 
 
 
December 16, 2016 
 
 
 
 
 
  
ABSTRACT 
 
Objective: The objective of the selective EBM review is to determine whether or not “Is 
radiofrequency ablation effective in treating Barrett’s esophagus patients with high-grade 
dysplasia?”  
 
Study Design: Review of two randomized controlled trials and one cohort study. All three 
studies were published in English in peer-reviewed journals after 2000. 
 
Data Sources: Two randomized controlled trials and one cohort study found via PubMed.  
 
Outcome(s) Measured: All three studies measured eradication of dysplasia via biopsy 
evaluation. Other outcomes measured included progression to high-grade dysplasia or 
adenocarcinoma based on histology findings, overall cancer risk based on observations of 
patients in the registry, and rate of serious adverse events determined by any event that led to 
death or required hospitalization. 
 
Results: Phoa et. al and Haidry et. al found that RFA treatment was successful in treating 
dysplastic Barrett’s esophagus. Though Shaheen et. al found that RFA treatment was successful 
in eradication of dysplasia, given the poor study design and lack of control group, it cannot be 
concluded whether or not RFA treatment was successful for patients with high-grade dysplasia.  
 
Conclusions:  Based on the results of the Haidry and Phoa studies, RFA was shown to be an 
successful and cost-effective treatment method for the eradication of dysplastic Barrett’s 
esophagus. The Shaheen study found that RFA was effective, however it is difficult to assess 
validity of the data due to lack of a control group throughout the entirety of the study. 
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1 
INTRODUCTION 
 
Barrett’s esophagus (BE) is “the replacement of normal esophageal squamous mucosa by 
specialized intestinal columnar mucosa,” a complication of longstanding gastroesophageal reflux 
disease (GERD) that is seen in about 10 to 15% of patients, increasing patients’ risk of 
developing esophageal adenocarcinoma.
4,10
 Some patients with Barrett’s esophagus may develop 
dysplasia, a precancerous change in the lining of the esophagus - though risk of developing 
cancer is low at just “0.5 percent per year.”10 This paper evaluates two randomized controlled 
trials (RCTs) and one cohort study evaluating the efficacy of radiofrequency ablation (RFA) as a 
method of eradicating high-grade dysplasia in patients with Barrett’s esophagus. 
The prevalence of Barrett’s esophagus is about 1.6% of the general population.8 In the 
United States, adenocarcinoma of the esophagus is becoming more prevalent and is most often 
seen in obese, Caucasian males, with a history of GERD.
10
 Though both photodynamic therapy 
(PDT) and RFA are successful in treating dysplastic BE, success rates of eradication are higher 
with RFA and “five times less costly than PDT.”1 RFA treatment course involves 2 to 3 sessions 
1 to 4 times per year, with an average of 2 to 4 days of missed work per session. Given its short 
recovery time, it is a cost-effective option for the treatment of dysplasia.
5
 
Though the exact cause of Barrett’s esophagus is unknown, history of longstanding 
GERD increases the risk of developing the condition.
10
 When a patient is diagnosed with 
Barrett’s esophagus, a periodic endoscopy is the next step in management of this condition. If the 
endoscopy does not show evidence of dysplasia, it should be repeated approximately every three 
years.
10
 Typically first line treatment begins with high dose proton pump inhibitors or histamine 
blockers.
9
 For high-grade dysplasia or cancer, esophagectomy is an option.
2
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Once Barrett’s esophagus progresses to some form of dysplasia, more serious measures 
must be taken to prevent further advancement to adenocarcinoma of the esophagus. One such 
measure is RFA, which compared to PDT has a smaller side effect profile and costs less. In 
addition, RFA can be controlled to a specified depth.
1
 
OBJECTIVE 
 
The objective of this selective EBM review is to determine whether or not “Is 
radiofrequency ablation effective in treating Barrett’s esophagus patients with high-grade 
dysplasia?” 
METHODS 
 
This review focuses on patients over the age of 18 with Barrett’s esophagus and 
endoscopic evidence of dysplasia, where all studies focus on RFA as the primary intervention. 
Shaheen et. al focus on RFA compared to a sham endoscopic procedure.
7
 Haidry et. al focus on 
RFA and endoscopic mucosal resection in a cohort study.
3
 Phoa et. al focus on RFA compared to 
endoscopic surveillance (high-resolution endoscopy).
6
 Many outcomes are measured including 
progression to high-grade dysplasia or adenocarcinoma, eradication of dysplasia, durability of 
response, adverse reactions, and overall cancer risk.  Two of the studies are RCTs and one is a 
cohort study. All articles are published in English and in peer-reviewed journals found via 
Pubmed using keyword searches such as “Barrett’s esophagus”, “radiofrequency ablation,” and 
“dysplasia.” Inclusion criteria include articles published after the year 2000. Exclusion criteria 
include patients under the age of 18 and history of malignancy. All articles are selected based on 
relevance to the clinical question and inclusion of patient oriented outcomes (POEMs). Statistical 
analysis is reported using Cox proportion hazard models, t tests, Kaplan-Meier survival curves, 
χ2 tests, Fisher’s exact test, p value, NNT, and SD.3,6,7 
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Table 1 – demographics and characteristics of included studies  
Study Type # Pts Inclusion Criteria Exclusion Criteria W/D Interventions 
Haidry 
(2015)
3
 
Cohort 920 Men and non-
pregnant women over 
the age of 21 years 
with no 
contraindications to 
endoscopy. 
Pregnant women, 
contraindications to 
endoscopy, <21 years 
of age. 
412 Radiofrequency 
ablation and 
endoscopic 
mucosal 
resection 
Phoa 
(2014)
6
 
RCT 136  Prior endoscopic 
treatment for Barrett 
esophagus; history of 
high-grade dysplasia 
or adenocarcinoma; 
active secondary 
malignancy; estimated 
life expectancy less 
than 2 years; age of 18 
years or younger or 85 
years and older. 
7 Radiofrequency 
ablation 
Shaheen 
(2011)
7
 
RCT 127 Endoscopically 
evident, non-nodular, 
dysplastic BE <8cm 
in length; 18-80 y/o; 
for subjects with 
HGD, additional 
requirement of 
endoscopic US 
negative for 
lymphadenopathy or 
esophageal wall 
abnormalities within 
12 months of 
enrollment; previous 
EMR permissible >8 
weeks before entry, 
provided that 
subsequent 
endoscopy 
demonstrated non-
nodular dysplasia. 
Pregnancy; active 
esophagitis or 
stricture; history of 
esophageal 
malignancy, varices, 
uncontrolled 
coagulopathy, or life 
expectancy of <2 
years, as judged by the 
investigator. 
10 Radiofrequency 
ablation 
 
 
 
 
 
 
Karnado, RFA treatment for dysplastic BE 
 
4 
OUTCOMES MEASURED 
 
 Outcomes measured are those that focus on patient oriented evidence that matters 
(POEM). All three studies measure eradication of dysplasia via biopsy evaluation.
3,6,7
 Other 
outcomes measured include progression to high-grade dysplasia or adenocarcinoma based on 
histology findings, overall cancer risk based on observations of patients within the registry, and 
rate of serious adverse events determined by any event that led to death or required 
hospitalization.
3,6,7
 
RESULTS 
 
This review examines two RCTs and one cohort study that evaluate RFA as a method of 
eradication of dysplasia in Barrett’s esophagus patients. The results of the two RCTs are reported 
as dichotomous data, so numbers needed to treat (NNT), relative benefit increase (RBI), and 
absolute benefit increase (ABI) are calculated. The results from the cohort study cannot be 
converted to dichotomous data.  
In the Shaheen study, 127 subjects were divided into either a low-grade dysplasia (LGD) 
or a high-grade dysplasia (HGD) group.
7
 Inclusion and exclusion criteria can be found in Table 
1. Subjects were then randomized to receive either the sham endoscopic procedure (SHAM) or 
the RFA treatment. Subjects in the experimental group received up to 4 RFA treatments at 0, 2, 
4, and 9 months based on results from the biopsies, and 1 treatment in the second year. After one 
year, 117 of the subjects completed follow up and 35 of the 39 subjects in the SHAM group were 
“eligible for cross-over to the RFA treatment.”7 The remaining 4 participants developed 
esophageal adenocarcinoma and were no longer eligible for crossover treatment. In the second 
trial, 119 subjects underwent RFA, and 106 subjects made it to the 2-year follow up. The 
primary outcome measured was whether or not complete eradication of dysplasia could be 
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achieved. After 2 years, 51/52 (98%) subjects with low-grade dysplasia achieved complete 
eradication and 50/54 (95%) subjects with high-grade dysplasia achieved complete eradication. 
The results from the study can be found in Table 2.  
Due to the crossover treatment option after one year, there was no longer a control group 
at the end of the study. Therefore, values in Table 2 were calculated using the low-grade 
dysplasia group as the control and the high-grade dysplasia group as the experimental group. 
NNT was calculated to be -33, meaning for every 33 patients treated with RFA, one fewer would 
achieve complete eradication of high-grade dysplasia. Given the poor study design, it is difficult 
to assess whether or not RFA treatment was successful in eradication of high-grade dysplasia, as 
there was no control group at the end of the study and therefore no reported p value. Upper 
gastrointestinal hemorrhage and chest discomfort with nausea were the most common adverse 
events noted after the study. No “procedure-related” deaths occurred.7 
Table 2. Treatment Effects 
STUDY CER EER RBI ABI NNT 
Shaheen
7
 .98 .95 -0.031 -0.03 -33 
Phoa
6
 .279 .926 2.32 .647 1.545 
 
In the Phoa study, 140 subjects were randomized to either the experimental group, where 
they received RFA, or the control group, for endoscopic surveillance.
6
 Patients in the 
experimental group were treated with either a circumferential or a focal device based on the 
degree of their disease. RFA sessions were scheduled every 3 months until there was complete 
eradication of dysplasia. Follow up endoscopy was 3 months after the last therapy session, where 
biopsy samples were taken. The experimental group also received “double-dose proton pump 
inhibition as maintenance therapy.”6 Patients in the control group “underwent high-resolution 
endoscopy.”6 One subject in the RFA group progressed to adenocarcinoma and was treated with 
endoscopic resection. This study found that RFA treatment was successful in treating BE 
Karnado, RFA treatment for dysplastic BE 
 
6 
dysplasia, with a statistically significant p value <0.001. Results from the study can be found in 
Table 3. Esophageal stricture, bleeding, mucosal laceration, and abdominal pain were the noted 
adverse events.
6
  
Table 3. Complete Eradication of Dysplasia 
STUDY P-VALUE OR 95% CI RR 
Haidry
3
 P <0.0001 1.103 1.023 to 1.190 N/A 
Phoa
6
 P <0.001 N/A 59.4-81.6% 90% 
 
In the Haidry cohort study, 920 patients within the UK registry were referred for 
treatment – 508 completed treatment.3 RFA was completed with either a circumferential or with 
several focal devices for shorter segments of Barrett’s esophagus. Patients received an average of 
2 to 3 RFA treatments. At the end of protocol, patients without dysplasia were followed every 3 
months for post-RFA surveillance during the first year, every 6 months for the following year, 
and then annually after that. From 2008-2010, 206/266 (77%) of all patients achieved complete 
eradication of dysplasia at the end of protocol.
3
 From 2011-2013, 222/242 (92%) of all patients 
achieved complete eradication of dysplasia at the end of protocol.
3
 From 2008-2010 and then 
from 2011-2013, 76% and 92% of patients with high-grade dysplasia (HGD) achieved complete 
eradication respectively.
3
 These results were statistically significant, as the p value was less than 
0.0001. Results can be found in Table 3. 
DISCUSSION 
 
Radiofrequency ablation is an “endoscopic technique in which diseased tissue is exposed 
to heat energy and destroyed.”2 RFA is generally used as a treatment for Barrett’s esophagus. 
The procedure lasts about 25-50 minutes and on average, patients have anywhere from 2 to 3.5 
treatments. Commonly after treatment, patients complain about “chest discomfort, sore throat 
and/or painful or difficult swallowing after the procedure.”5 Although RFA is considered a 
generally safe procedure, and complications are seen in <1% of patients, there is always a 
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possible risk of esophageal stricture, bleeding, infection, and death.
2,5
 Eradication rates range 
from 72-100%.
5
  
CONCLUSION 
 
After careful review of these three studies, there is evidence in both the Phoa and Haidry 
studies to suggest that radiofrequency ablation is a safe and effective treatment for patients with 
endoscopic evidence of Barrett’s esophagus with dysplasia. Future research, however, is 
warranted and should focus more on patients with high-grade dysplasia. Although the subjects in 
the Shaheen study did see improvement in their dysplasia after the RFA treatments, due to the 
poor study design and lack of control group at the end of the study, it is difficult to conclude 
whether or not RFA was an effective treatment for patients with high-grade dysplasia. Compared 
to other therapies, including PDT, RFA has a smaller side effect profile and costs less.
1
 The 
studies each maintained appropriate follow up time with the subjects.  
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